HMGB1 and rectal cancer: The study by Bains et al. is interesting and suggests change in serum HMGB1 over the course of multimodal neoadjuvant treatment for rectal cancer (with ICD inducers – oxaliplatin, radiation) predicts metastatic failure, and this must be explored in a larger cohort of patients (see supplementary Table 2).